WO2000071987A2 - Isolation and culturing of fetal cells - Google Patents
Isolation and culturing of fetal cells Download PDFInfo
- Publication number
- WO2000071987A2 WO2000071987A2 PCT/DK2000/000281 DK0000281W WO0071987A2 WO 2000071987 A2 WO2000071987 A2 WO 2000071987A2 DK 0000281 W DK0000281 W DK 0000281W WO 0071987 A2 WO0071987 A2 WO 0071987A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- fetal
- maternal
- antibodies
- fetal cells
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
Definitions
- the present invention relates to a method for isolating fetal cells from maternal blood, in particular from maternal blood not having been subjected to concentration or enrichment.
- the invention relates to a method for culturing fetal cells.
- Fetal cells may be obtained by amniocentesis, the removal of amniotic fluid from the amniotic cavity within the amniotic sac or by chorion biopsy, where biopsies are taken from the placenta, a so-called invasive sampling.
- fetal cells During pregnancy a variety of cell types of fetal origin cross the placenta and circulate within maternal peripheral blood. The feasability of using fetal cells in the maternal circulation for diagnostic purposes has been hindered by the fact that fetal cells are present in maternal blood in only very limited numbers, reported numbers have been from 1 :10 5 to 1 :10 8 fetal cells per nucleated maternal cells. In addition most fetal cells cannot be distinguished from maternal cells on the basis of morphology alone, but rather must be identified based upon detection of fetal cell markers. However, it would be advantageously to perform fetal diagnosis by a non-invasive procedure, such as a maternal blood sample.
- fetal leukocytes are one subpopulation of white blood cells found in the blood. There are three types of subsets of leukocytes (which also are referred to as poiymorphnuclear leukocytes): neutrophils, basophils and eosinophils. All leukocytes have a distinctive morphology characterized by the nucleus and cellular granules.
- Yet another method of removing maternal cells, in particular maternal erythrocytes, is by iysing, again optionally combined with immunologic methods for removing the maternal cells.
- Another selection procedure is positive selection, for example by use of CD71 antibodies.
- SUBSTIT 273, R 1829 culture was used as part of their isolation method and male cells were found after various sorting/enrichment procedures. Also Jansen et al, (Prenatal Diagnosis, 1999, 19, 323) developed a method for culturing cord blood cells in a model system for isolation of fetal nucleated red blood cells. However, none of the methods have shown a significant increase in fetal cells after culture.
- the present invention reveals a novel method of isolating fetal cells from maternal blood.
- the present method has proven to be optimised in relation to isolating meth- ods described in the prior art, and the present invention represents a method having beneficial properties technically and financially.
- the present invention presents a method wherein fetal cells are isolated from maternal blood without prior enrichment or concentration of the sample, providing for a method of isolation by which the risk of los- ing fetal cells due to enrichment or concentration procedure has been reduced.
- maternal red blood cells A major difference between maternal and fetal red blood cells is the latter having a nucleus, i.e. maternal red blood ceils are anucleated. Furthermore, maternal blood contains three types of nucleated fetal cells, nucleated erythrocytes, syncytiotropho- blasts and leukocytes. It is an object of the present invention to provide for a method
- At most 50 % of the maternal cells of the maternal blood sample have been removed or will be removed before or after the labelling of the fetal cells, thus that substantially no enrichment of the sample is carried out before identification of the cells.
- at most 20 % of the maternal cells have been removed, such as at the most 15% of the maternal cells, such as at most 10 % of the maternal cells, more preferred at most 5 % of the maternal cells, more preferably at most 2.5 % of the maternal cells, most preferred at most 1 % of the maternal cells.
- the sample may be used as such directly after taking the maternal blood sample.
- the size of the maternal blood sample is preferably in the range of 0,5 to 40 ml, such as in the range of 5 to 40 ml, such as from 10 to 30 ml.
- the sample may be diluted at least 1.5 times, such as twice, more preferred at least three times, such as five times by adding isotonic buffers, such as saline solutions,
- the selective labelling of the fetal cells may be carried out by any suitable method.
- Fetal cells may be distinguished from maternal cells by the specific recognition of a fetal cell antigen or they may be distinguished by staining with a labelled antibody to a protein selectively produced by fetal cells or they may be distinguished from maternal cells by the specific recognition of DNA or RNA encoding a protein selectively or substantially selectively produced by fetal cells.
- fetal-cell-specific RNA sequences are used as fetal cell markers.
- RNA is generally messenger RNA (mRNA).
- the presence of such RNA indicates that the gene for the fetal protein is being transcribed and expressed.
- the probes used to identify fetal cells in a sample containing fetal and maternal cells include nucleic acid molecules, which comprise the nucleotide sequence complementary to the nucleotide sequence of the RNA molecule encoding a specific protein.
- Fetal cells contain distinct mRNAs or RNA species that do not occur in other cell types. The detection of these RNAs, whether as mRNA can serve to identify cells, or even subcellular fractions of cells fetal or embryonic in origin).
- the m-RNA to be detected may be coding for a protein selected from the group consisting of embryonic hemoglobin, such as ⁇ and zeta globin chains, and fetal hemoglobin, such as gamma and alpha globin chains.
- DNA probes (oligos) for the hybridisation are directed against embryonic cell RNA, such as for ⁇ and zeta globin chains, and for fetal hemoglobin, such as for gamma and alpha globin chains.
- a DNA probe may be synthesised as an oligodeoxynucleotide using a commercial synthesiser. Probes may be comprised of the natural nucleotide bases or known analogues of the natural nucleotide bases.
- hybridisation probe for the DNA or RNA discussed above is selected from peptide nucleic acid (PNA) probes and other synthetic molecules capable of Watson Crick-base pairing with the fetal m-RNA
- the probe as discussed above such as a synthetic DNA probe, is directly labelled, by having fluorochromes covalently attached thereto
- the binding of such probes to the cell may be observed under a microscope as a bright fluorescence or may be detected by a fluorimet ⁇ c apparatus
- the probes are indirectly labelled with biotin or enzymes for example, such as alkaline phosphatase
- RNA populations are present in high abundance and other fetal or embryonic-specific RNAs are present in low abundance Several RNA species occur simultanously in fetal cells as opposed to maternal cells. This provides for yet an- other method of enhancing the distinction between fetal cells and non-fetal cells by the detection of multiple RNA species
- Two or more RNA species may be detected using one or more probes for a first RNA sequence and one or more probes for a second RNA sequence
- the probes for the first sequence are labelled to provide a first signal, such as a greenish fluorescence
- the probes for the second se- quence are labelled to provide a signal that is different from the first signal, such as a reddish fluorescence
- the selective labelling is based on an antigen-antibody reaction with a protein selectively produced by fetal cells
- a protein selectively produced by fetal cells
- Such a protein may be selected from the group consisting of embryonic hemoglobin, such as ⁇ and zeta globin chains, and fetal hemoglobin, such as gamma and alpha globin chains
- the labelling may be carried out by the use of an antibody selected from antibodies against various types of normal globin chains in human hemoglobin, for example anti epsilon ( ⁇ ) antibodies, such as monoclonal unlabelled antibodies, monoclonal biotin labelled antibodies, monoclonal biotin and fluorochrome labelled antibodies, and monoclonal fluorochrome labelled antibodies, anti zeta ( ⁇ ) antibodies, such as monoclonal unlabelled antibodies, monoclonal biotin labelled antibodies, monoclonal fluorochrome labeled antibodies, and polyclonal fluorochrome labeled antibodies, anti gamma ( ⁇ ) antibodies, such as polyclonal (sheep) antibodies, such as monoclonal unlabelled antibodies, monoclonal biotin labelled antibodies, monoclonal fluorochrome labeled antibodies, and polyclonal fluorochrome labeled antibodies, anti alpha ( ⁇ ) antibodies, and anti beta ( ⁇ ) antibodies.
- ⁇ antibodies such as monoclonal unlabelled
- the fluorochrome is selected to be excited in the wave-length area of the detection means, and furthermore in suitable combination with an optional second labelling.
- the fluorochromes may be selected from FITC (fluorescein- isofluocyanate) or TRITC (Rhodanine Tetramethyl- isofluocyanate) having excitation at 495 nm and 555 nm, respectively.
- the labelling is carried out using anti epsilon ( ⁇ ) monoclonal antibodies or anti zeta ( ⁇ ) monoclonal antibodies, more preferably anti epsilon ( ⁇ ) unlabelled monoclonal antibodies or anti zeta ( ⁇ ) unlabelled monoclonal antibodies, or anti epsilon ( ⁇ ) monoclonal biotin labelled antibodies or anti zeta ( ⁇ ) monoclonal biotin labelled antibodies.
- the unlabelled antibodies are used as known in the art, by using a second labelling step with eg. second antibodies against the unlabelled antibody, said antibody being labelled as discussed above, such as fluorochrome labelled.
- a second labelling step with eg. second antibodies against the unlabelled antibody, said antibody being labelled as discussed above, such as fluorochrome labelled.
- the labelling is performed using anti gamma ( ⁇ ) fluorochrome labeled antibodies, such as FITC labelled antibodies.
- two or more selective labellings may be performed.
- the combination of two or more labellings may be a combination of
- the combined labelling may be carried out by the use of two or more different hybridisation probes, such as a combination of a DNA probe and a PNA probe for hybridisation with the same fetal RNA or more preferred with different RNAs. Also, two or more different DNA probes (or PNA probes) may be used for hybridisation with different fetal
- the enhanced selective labelling may also by carried out by the use of two or more antibodies directed against the same protein or different proteins.
- the labelling with two or more labels may be carried out simultaneously.
- a combination of an immunological labelling and a hybridisation labelling may be employed according to the present invention.
- the labelling is normally carried out sequentially by a first immunological labelling step, then identification of the labelled cells, and then a second step of hybridisation labelling for verification of the identification of the cells labelled by the first step. It is preferred in the first step to use antibodies against gamma globin and in the second step to use hybridisation for epsilon and/or zeta globin and/or gamma mRNA to verify the fetal cells identified.
- the verification may be conducted by a second step of staining the cell nucleus since the maternal cells probable to be detected will be anucleated maternal cells, i.e. maternal erythrocytes.
- the nucleus staining is selected from 4,6-diamidino-2-phenylindole (DAPI) or propidium-iodide (PI).
- An important feature of the present invention is the identification of the labelled fetal ceils without the sample being enriched or concentrated with respect to the fetal cells in order to avoid loss of fetal cells. Accordingly, the method according to the present invention comprises identification of the selectively labelled fetal cells.
- the identification is performed by spreading the blood sample on a solid surface and detecting the labelled cells on the surface.
- the detection may be carried out by any suitable means in accordance with the labelling method in ques-
- Support materials according to the invention preferably comprise glass, nylon, nitrocellulose and Scotch tape, and any suitable membranes, such as filtermembranes.
- the collected samples are spread on a support surface in a monolayer for the cells not to overlap one another.
- the in situ hybridization process according to the invention may car- ried out on fetal cells attached to a solid support.
- the antibodies may be coupled to numerous solid surfaces or supports/substrates, such as containers, columns, wells, beads, or particles by physical or chemical bonding.
- the antibodies may be coupled to a compound which facilitates the separation step.
- antibodies may be labelled with fluorescent markers and cells to which these labelled antibodies bind may thereby be separated with a cell sorter according to known procedures.
- the nucleic acid of the fetal cells can be amplified prior to detection using a known amplification technique, such as the polymerase chain reaction (PCR).
- Primers for PCR amplification are chosen to specifically amplify a DNA of interest in the fetal DNA.
- the rate of cells identified per unit of time is the rate of cells identified per unit of time.
- very fast scanning microscopes may be used for the identification.
- laser scanners could be used.
- the laser scanner is equipped with at least two lasers emitting light with different wavelength capable to excite the various labels on the cells or in one laser emitting several wavelengths.
- SUBSTITUTE SHEET fRULE Preferably, during or after identification of the fetal cells the position of detected labelled cells on the surface is recorded. This provides for the later collection of the detected cells from the position which has been recorded.
- the position of the detected labelled cells on the supporting surface may be recorded by use of a scanner provided with detectors registering the light emitted from the labelled cells, such photo-multipliers, CCDs, or the like detectors. Thereby it is possible to identify and specifically isolate substantially only the selectively labelled fetal cells.
- the scanner is arranged for detecting selectively labelled fetal cells, and when detecting a fetal cell, carrying out a verification step by switching to another wavelength to verify presence of for example staining of the nucleus.
- a fast scanning system for example a scanner capable of scanning in the range of from 0.1 m/sec to 10 m/sec or faster, such as appr. 1 m/sec.
- the cells collected according to any of the procedures may be subjected to further identification and/or investigation, such as microscopic and/or molecular identification and/or investigation.
- the cells may be subjected to investigations of analysing the presence of genetic diseases, for example.
- the nucleic acid of fetal cells may be analysed for diagnostic or other purposes. For instance the presence or absence of a gene or a gene mutation may indicate the presence of diseases, such as cystic fibrosis.
- the nucleic acid may additionally be analysed for X or Y specificity. Thus, the presence of a Y chromosome encoded genes or gene products is a qualitative distinguishing feature of the cells of a male fetus.
- Verification of the selective identification of fetal cells may be carried out by several methods.
- the method may be performed on maternal blood samples from pregnant women carrying a male fetus.
- the cells isolated may then be analysed for the presence of a Y chromosome, indicative of cells being from the male fetus.
- Another verification method which is usable independent of the sex of the fetus, is verification by use of identification of small tandem repeats (STR) or variable number tandem repeats (VNTR) to detect genetic input from the father, thereby verifying fetal cells, as the only cells in the sample comprising input from the father.
- STR small tandem repeats
- VNTR variable number tandem repeats
- SUBSTITUTE S fRULE As may be understood from the above the present method may be carried out for the isolation of any kind of rare event cells in a blood sample, and is particular interesting when used for rare event cells being present in very low concentrations, such as those for the fetal cells in maternal blood. This may for example also be true for some cancer forms.
- a method for multiplying fetal blood cells, preferably fetal red blood cells, in a cell culture comprising fetal blood cells and other cells, in particular maternal blood cells may be employed.
- the cultivation may be carried out on any sample comprising fetal blood cells, such as umbilical cord samples from aborted fetuses, or maternal blood samples.
- the multiplication of the fetal cells is desirable to achieve due to the use of the pres- ent invention.
- the method according to the invention comprises performing the cell culturing in a culture medium containing growth factors necessary for the multiplication of fetal cells.
- the multiplication may be conducted by any suitable method as known to the per- son skilled in the art.
- the method of culturing fetal cells may be combined with the method of selectively isolating fetal cells in any suitable manner. Accordingly, a maternal blood sample may be subjected to cultivation of fetal cells before subjecting the sample to label- ling, identification and isolation of the fetal cells. Thereby the starting concentrations of fetal cells in the maternal blood sample are increased without removing any cells originating from the mother.
- the culture method may also be used in connection with analysis of maternal blood samples that have been pretreated in order to remove some of the maternal cells.
- the culture method may be conducted on fetal cells having been identified and isolated according to the isolation method described above, in order to increase the amount of fetal cells for further analysis.
- the fetal cells may be harvested by any suitable method. In case the colonies obtained are harvested collectively, there will be a very high number of cells of which only some will be from the fetus. Contrary to this, colonies may be harvested individually to increase the rate of fetal cells in the harvested material.
- the invention relates to a method of diagnosing a disease in a fetus comprising obtaining a blood sample from the woman pregnant with said fetus, whereby at most 50 % of the maternal nucleated cells have been removed and/or at most 50 % of the maternal anucleated cells have been removed from said blood sample, selectively labelling the fetal cells in the maternal blood sample, identifying the selectively labelled fetal cells, specifically labelling with at least one disease marker the identified fetal cells for diseases, and identifying specifically labelled cells.
- the selective labelling and identification of the cells are carried out as described above.
- the specific labelling with at least one disease marker refers to the labelling of the identified cells with a marker, such as a probe, to a gene or a gene mutation specific for the genetic disease or a chromosome abnormality to be diagnosed.
- the fetal cells are isolated before specifically labelling the fetal cells.
- the present invention relates to the use of the present method for diagnosing a disease of the fetus, such as a genetic disease.
- the genetic disease may be any genetic disease or a chromosome abnormality, such as cystic fibrosis, hemophilia, muscular dystrophy, Down' syndrome, Klinefelter, or Turner' syndrome.
- the invention is further exemplified by the following non-limiting examples.
- the blood is fixed according to table I below and mounted on slides as described.
- the slides prepared are stained with antibodies against globin chains and embryonic globin chains as described below in table II.
- Vectashield is a trademark to Vector Laboratories, USA.
- SUBSTITUTE SHEET fRULE 26 After staining the slides may be stored for later identification of the fetal cells. The identification may be carried out in a laser scanner.
- Pheripheral venous blood is obtained from the pregnant woman.
- Slides are prepared by smearing the blood on poly-L-lysine coated slides, whereafter the slides are stored individually in plastic bags at -20 °C. The fixation is carried out as described in table III.
- Antibody staining and identification is as described in example 1. The cell morphology is maintained more consistently when mounting on slides before fixation is carried out.
- Fetal cells were diagnosed by the Y chromosome FISH analysis by the following procedure:
- Maternal whole blood is smeared onto a slide, and fixed 2 minutes in paraformaldehyde (2 %) at room temperature.
- the cells are permeabilised 10 minutes in acetone at -20 °C, and then washed 3 minutes in PBS-buffer at room temperature.
- the slides are dehydrated in 62%, 96% and 99% alcohol at room temperature, and air- dried.
- a DNA probe 'pBAM-X' for the X-chromosome labelled with digoxigenin and a DNA probe 'ph-y 2,1' for the Y-chromosome labelled with biotin are used.
- the slide is placed on a heating plate at 37 °C, and the probe is added to the slide and a
- the slide is incubated 20 minutes at 37 °C with fluorescein-labelled avidin/rhodamin labelled anti-digoxigenin, and then washed 5 minutes in 4xSSC/0.1% tween 20, rinsed in 2xSSC and air dryed.
- the slide is then mounted in Vectashield with counterstain added (DAPI or PI).
- the identification of cells is as described in example 1.
- the verification method may alternatively be a diagnostic method using probes relevant for the diseases and/or chromosome abnormalities to diagnose.
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002413835A CA2413835A1 (en) | 1999-05-25 | 2000-05-25 | Isolation and culturing of fetal cells |
AU47452/00A AU4745200A (en) | 1999-05-25 | 2000-05-25 | Isolation and culturing of fetal cells |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99201651.9 | 1999-05-25 | ||
EP99201651 | 1999-05-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000071987A2 true WO2000071987A2 (en) | 2000-11-30 |
WO2000071987A3 WO2000071987A3 (en) | 2001-04-19 |
Family
ID=8240233
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DK2000/000281 WO2000071987A2 (en) | 1999-05-25 | 2000-05-25 | Isolation and culturing of fetal cells |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU4745200A (en) |
CA (1) | CA2413835A1 (en) |
WO (1) | WO2000071987A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011075774A1 (en) | 2009-12-23 | 2011-06-30 | Genetic Technologies Limited | Methods of enriching and detecting fetal nucleic acids |
WO2013192620A1 (en) | 2012-06-22 | 2013-12-27 | Quantrx Biomedical Corporation | Method for obtaining fetal cells and fetal cellular components |
US9447467B2 (en) | 2009-04-21 | 2016-09-20 | Genetic Technologies Limited | Methods for obtaining fetal genetic material |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995009245A1 (en) * | 1993-09-27 | 1995-04-06 | Oncor, Inc. | Methods for detecting and analyzing individual rare cells in a population |
US5447842A (en) * | 1990-03-27 | 1995-09-05 | Genetype A.G. | Fetal cell recovery method |
WO1996027132A1 (en) * | 1995-02-28 | 1996-09-06 | Immunivest Corporation | Affinity-binding separation and release of one or more selected subset of biological entities from a mixed population thereof |
EP0791659A2 (en) * | 1989-11-13 | 1997-08-27 | Children's Medical Center Corporation | Antigen specific separation of nucleated fetal cells in non-invasive detection of fetal DNA |
US5731156A (en) * | 1996-10-21 | 1998-03-24 | Applied Imaging, Inc. | Use of anti-embryonic hemoglobin antibodies to identify fetal cells |
US5750339A (en) * | 1994-11-30 | 1998-05-12 | Thomas Jefferson University | Methods for identifying fetal cells |
WO1998040746A1 (en) * | 1997-03-08 | 1998-09-17 | The University Of Dundee | Prenatal diagnostic methods |
US5858649A (en) * | 1992-07-17 | 1999-01-12 | Aprogenex, Inc. | Amplification of mRNA for distinguishing fetal cells in maternal blood |
WO1999041613A1 (en) * | 1998-02-12 | 1999-08-19 | Immunivest | Methods and reagents for the rapid and efficient isolation of circulating cancer cells |
US5962234A (en) * | 1997-10-20 | 1999-10-05 | Applied Imaging Corporation | Use of anti-embryonic epsilon hemoglobin antibodies to identify fetal cells |
-
2000
- 2000-05-25 CA CA002413835A patent/CA2413835A1/en not_active Abandoned
- 2000-05-25 AU AU47452/00A patent/AU4745200A/en not_active Abandoned
- 2000-05-25 WO PCT/DK2000/000281 patent/WO2000071987A2/en active Application Filing
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0791659A2 (en) * | 1989-11-13 | 1997-08-27 | Children's Medical Center Corporation | Antigen specific separation of nucleated fetal cells in non-invasive detection of fetal DNA |
US5447842A (en) * | 1990-03-27 | 1995-09-05 | Genetype A.G. | Fetal cell recovery method |
US5858649A (en) * | 1992-07-17 | 1999-01-12 | Aprogenex, Inc. | Amplification of mRNA for distinguishing fetal cells in maternal blood |
WO1995009245A1 (en) * | 1993-09-27 | 1995-04-06 | Oncor, Inc. | Methods for detecting and analyzing individual rare cells in a population |
US5750339A (en) * | 1994-11-30 | 1998-05-12 | Thomas Jefferson University | Methods for identifying fetal cells |
WO1996027132A1 (en) * | 1995-02-28 | 1996-09-06 | Immunivest Corporation | Affinity-binding separation and release of one or more selected subset of biological entities from a mixed population thereof |
US5731156A (en) * | 1996-10-21 | 1998-03-24 | Applied Imaging, Inc. | Use of anti-embryonic hemoglobin antibodies to identify fetal cells |
WO1998040746A1 (en) * | 1997-03-08 | 1998-09-17 | The University Of Dundee | Prenatal diagnostic methods |
US5962234A (en) * | 1997-10-20 | 1999-10-05 | Applied Imaging Corporation | Use of anti-embryonic epsilon hemoglobin antibodies to identify fetal cells |
WO1999041613A1 (en) * | 1998-02-12 | 1999-08-19 | Immunivest | Methods and reagents for the rapid and efficient isolation of circulating cancer cells |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9447467B2 (en) | 2009-04-21 | 2016-09-20 | Genetic Technologies Limited | Methods for obtaining fetal genetic material |
WO2011075774A1 (en) | 2009-12-23 | 2011-06-30 | Genetic Technologies Limited | Methods of enriching and detecting fetal nucleic acids |
WO2013192620A1 (en) | 2012-06-22 | 2013-12-27 | Quantrx Biomedical Corporation | Method for obtaining fetal cells and fetal cellular components |
US10058306B2 (en) | 2012-06-22 | 2018-08-28 | Preprogen, LLC | Method for obtaining fetal cells and fetal cellular components |
US10792018B2 (en) | 2012-06-22 | 2020-10-06 | Preprogen Llc | Method for obtaining fetal cells and fetal cellular components |
EP4008270A1 (en) | 2012-06-22 | 2022-06-08 | Preprogen LLC | Method for obtaining fetal cells and fetal cellular components |
Also Published As
Publication number | Publication date |
---|---|
WO2000071987A3 (en) | 2001-04-19 |
CA2413835A1 (en) | 2000-11-30 |
AU4745200A (en) | 2000-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2140278C (en) | Enriching and identyfing fetal cells in maternal blood for in situ hybridization | |
JP6310540B2 (en) | Enrichment and identification of fetal cells in maternal blood and ligands used therefor | |
US7651838B2 (en) | Prenatal diagnosis method on isolated foetal cell of maternal blood | |
US5629147A (en) | Enriching and identifying fetal cells in maternal blood for in situ hybridization | |
EP1172445A1 (en) | A method for direct genetic analysis of target cells by using fluorescence probes | |
US20030232377A1 (en) | Early noninvasive prenatal test for aneuploidies and heritable conditions | |
WO2008081451A2 (en) | Methods and kits for analyzing genetic material of a fetus | |
JPH05501612A (en) | Non-invasive methods for fetal DNA isolation and detection | |
WO1995003431A1 (en) | Enriching and identifying fetal cells in maternal blood for in situ hybridization | |
EP1891204B1 (en) | Method of fetal cell enrichment | |
WO2005047532A1 (en) | Improved method of performing genetic analyses on reproductive tract cell samples | |
Ståhlberg et al. | Unravelling the biological secrets of microchimerism by single-cell analysis | |
Hamada et al. | Mid‐trimester fetal sex determination from maternal peripheral blood by fluorescence in situ hybridization without enrichment of fetal cells | |
WO2000071987A2 (en) | Isolation and culturing of fetal cells | |
EP3192879A1 (en) | Method for detecting presence/absence of fetal chromosomal aneuploidy | |
WO2016042830A1 (en) | Method for analyzing fetal chromosome | |
Chiu et al. | Non-invasive prenatal diagnosis: on the horizon? | |
CN110938700B (en) | Method for evaluating or assisting in evaluating ovarian cells and marker used by method | |
CN107312779A (en) | For separate trophocyte aptamer, separate trophocyte method and chromosomal copy number analysis of variance method | |
EP3202912A1 (en) | Noninvasive method and system for determining fetal chromosomal aneuploidy | |
WO2023104773A1 (en) | Isolation and diagnostics of fetal cells | |
Chueh et al. | Prenatal diagnosis using fetal cells from the maternal circulation. | |
Babochkina | Fetal cells in maternal circulation: Fetal Cell Separation and FISH Analysis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000929324 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000929324 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09926603 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2413835 Country of ref document: CA |
|
NENP | Non-entry into the national phase in: |
Ref country code: JP |